[Combined fixed doses therapy in systemic hypertension].

Area of Science:

• Cardiology
• Pharmacology
• Clinical Hypertension Research

Background:

• Hypertension management often requires combination therapy for optimal blood pressure control.
• Fixed-dose combinations offer improved patient adherence and potentially additive therapeutic effects.
• Bisoprolol (B) is a cardioselective beta-blocker, and hydrochlorothiazide (HCTZ) is a thiazide diuretic with complementary antihypertensive mechanisms.

Purpose of the Study:

• To evaluate the efficacy and tolerability of initial combination therapy using fixed doses of bisoprolol and hydrochlorothiazide in patients with stage I and II hypertension.
• To assess the additive effects and sustained hypotensive response of the B/HCTZ combination over a 24-week treatment period.

Main Methods:

• A single-blind clinical trial involving 31 patients (22 female, 9 male; age 20-70 years) with stage I and II hypertension.
• Patients underwent a two-week washout and placebo period before initiating once-daily dosing of B 5 mg and HCTZ 6.25 mg for eight weeks.
• Dosage adjustments were made for non-responders, with a double dose of bisoprolol administered to patients whose blood pressure did not decrease below 90 mm Hg.

Main Results:

• The combination therapy resulted in a significant mean reduction in systolic/diastolic blood pressure of 23.9/20.1 mm Hg compared to baseline (p < 0.001).
• Adverse effects were infrequent, and no clinically significant changes in laboratory parameters were observed during the study.
• The B/HCTZ fixed-dose combination demonstrated a sustained hypotensive effect throughout the 24-week study period.

Conclusions:

• Fixed-dose combination therapy with bisoprolol (5 mg) and hydrochlorothiazide (6.25 mg) is an effective and well-tolerated treatment option for mild to moderate hypertension.
• This combination provides a sustained antihypertensive effect, making it a viable alternative for initial management of hypertension.